Evidence map›Paper›PMID 25639770›Full record

ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2015

NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report.

Howard M Shulman, Diana M Cardona, Joel K Greenson, Sangeeta Hingorani, Thomas Horn, Elisabeth Huber, Andreas Kreft, Thomas Longerich, Thomas Morton, David Myerson and 13 more

Open access · bronzeAbstract readConsensus Development Conference, NIH
In one paragraph

Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 124 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
124citing papers in PubMed, 2 pooled it
18.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

124 citing papers in PubMed, 2 syntheses or guidelines pooled it, 309 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

64 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 18 institutions in 3 countries.

Howard M ShulmanClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Diana M CardonaDepartment of Pathology, Duke University Medical Center, Durham, North Carolina.
Joel K GreensonDepartment of Pathology, University of Michigan, Ann Arbor, Michigan.
Sangeeta HingoraniClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Departments of Pediatrics, Gastroenterology and Pathology, University of Washington, Seattle, Washington; Seattle Children's Hospital, Seattle, Washington.
Thomas HornDepartment of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.
Elisabeth HuberInstitute of Pathology, University of Regensburg, Regensburg, Germany.
Andreas KreftInstitute of Pathology, University Medical Center Mainz, Mainz, Germany.
Thomas LongerichInstitute of Pathology, University Hospital RWTH Aachen, Aachen, Germany.
Thomas MortonDepartments of Pediatrics, Gastroenterology and Pathology, University of Washington, Seattle, Washington.
David MyersonClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Pathology, University of Washington, Seattle, Washington.
Victor G PrietoDepartment of Pathology, University of Texas M.D. Anderson Cancer Center, Houston, Texas.
Avi RosenbergLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Nathaniel TreisterDivision of Oral Medicine and Dentistry, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts.
Kay WashingtonDepartment of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, Tennessee.
Mirjana ZiemerDepartment of Dermatology, University Hospital of Leipzig, Leipzig, Germany.
Steven Z PavleticExperimental Transplantation and Immunology Branch, National Cancer Institute, Bethesda, Maryland.
Stephanie J LeeClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Mary E D FlowersClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Kirk R SchultzDepartment of Pediatrics, BC Children's Hospital/University of British Columbia, Vancouver, British Columbia.
Madan JagasiaDivision of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, Tennessee.
Paul J MartinClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Georgia B VogelsangDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
David E KleinerDepartment of Pathology, University of Texas M.D. Anderson Cancer Center, Houston, Texas. Electronic address: kleinerd@mail.nih.gov.
Fred Hutch Cancer Center · USThe University of Texas MD Anderson Cancer Center · USUniversity of Washington · USDana-Farber Brigham Cancer Center · USDuke University · USJohannes Gutenberg University Mainz · DEJohns Hopkins University · USMassachusetts General Hospital · USNational Cancer Institute · USNational Institutes of Health · USRWTH Aachen University · DESeattle Children's Hospital · USUniversity Hospital Leipzig · DEUniversity of British Columbia · CAUniversity of Michigan · USUniversity of Regensburg · DEVanderbilt University · USVanderbilt University Medical Center · US

Funding

VIRUS-MEDIATED MYELOSUPPRESSIONP01CA018029 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI STEPHANIE J LEE · 1985 to 2026
$128.4M
Improving Outcomes Assessment in Chronic GVHDR01CA118953 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI LEE, STEPHANIE J · 2011 to 2025
$8.3M
Improving Outcomes Assessment in Chronic GVHDU01CA118953 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI LEE, STEPHANIE J · 2007 to 2010
$3.1M
Intramural NIH HHS Z99 CA999999NCI NIH HHS CA118953NCI NIH HHS CA18029NCI NIH HHS P01 CA018029NCI NIH HHS U01 CA118953
6 · The paper itself

Abstract

The 2005 National Institute of Health (NIH) Consensus Conference outlined histopathological diagnostic criteria for the major organ systems affected by both acute and chronic graft-versus-host disease (GVHD). The 2014 Consensus Conference led to this updated document with new information from histopathological studies of GVHD in the gut, liver, skin, and oral mucosa and an expanded discussion of GVHD in the lungs and kidneys. The recommendations for final histological diagnostic categories have been simplified from 4 categories to 3: no GVHD, possible GVHD, and likely GVHD, based on better reproducibility achieved by combining the previous categories of "consistent with GVHD" and "definite GVHD" into the single category of "likely GVHD." Issues remain in the histopathological characterization of GVHD, particularly with respect to the threshold of histological changes required for diagnostic certainty. Guidance is provided for the incorporation of biopsy information into prospective clinical studies of GVHD, particularly with respect to biomarker validation.

Indexed as

Clinical Trials as TopicGraft vs Host DiseaseIntestinal DiseasesLiver DiseasesMouth DiseasesSkin DiseasesBiomarkersFemaleHumansMaleBiomarkersAllogeneic hematopoietic cell transplantationChronic graft-versus-host diseaseConsensusDiagnosisHistologyPathology

Identifiers

PMID25639770
PMCPMC4359636
OpenAlexW2012434943

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.